# Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

> **NCT03576820** · PHASE3 · UNKNOWN · sponsor: **New York City Health and Hospitals Corporation** · enrollment: 50 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Lidocaine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03576820
- **Lead sponsor:** New York City Health and Hospitals Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-15
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576820, "Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03576820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*